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 1. Introduction 
Acute encephalopathy with onset of febrile convulsive status epilepticus has mainly 
been reported in East Asia and is classified into several subtypes according to the 
clinical course and neuroimaging findings. Acute encephalopathy with onset of febrile 
convulsive status epilepticus can be difficult to distinguish from febrile seizure status 
and often results in severe neurological dysfunction. In some patients with acute 
encephalopathy with onset of febrile convulsive status, the epilepticus shows a biphasic 
course, and such cases are designated as acute encephalopathy with biphasic seizures 
and late reduced diffusion (AESD) (Takanashi et al. 2006). AESD is clinically 
characterized by prolonged (>30 min) febrile seizures as the initial neurological 
symptom on day 1, followed by secondary seizures (most often in a cluster of complex 
partial seizures) associated with deterioration of consciousness level at days 4 to 6. 
Between the biphasic seizures, most patients present continuous disturbance of 
consciousness level, but some patients have normal, clear consciousness with no 
neurological symptoms, which may lead to an initial misdiagnosis of febrile seizure 
status. MRI shows no acute abnormality during the first two days, but reduced diffusion 
appears in the subcortical white matter during days 3 to 9 (Takanashi et al. 2006; 
Takanashi 2009; Watanabe et al. 2014).  
One possible cause of acute encephalopathy is depletion of energy resulting from 
decreased mitochondrial function (Mizuguchi et al. 2007). In mitochondrial diseases, 
various vitamins and coenzymes have been used clinically based on their effects on 
energy shortage and oxidative stress (Pfeffer et al. 2012), and effectiveness has been 
reported at high doses (Panetta et al. 2004). Therefore, this study aimed to examine the 
efficacy of a combination of vitamin B1, vitamin C, biotin, vitamin E), coenzyme Q10, 
and L-carnitine as a mitochondrial drug cocktail in the treatment of acute 
encephalopathy.  
2. Methods 
We defined acute encephalopathy based on criteria that have been reported as follows: 
(a) acute onset of severe and sustained impairment of consciousness after a preceding 
infection and (b) exclusion of CNS inflammation (Hoshino et al. 2012; Mizuguchi 
2013; Saitoh et al 2014 ), in addition to level of consciousness equal to or below 13 on 
the Glasgow Coma Scale and duration of impairment longer than 24 hours, according to 
the diagnostic criteria of the Japanese research committee on influenza encephalopathy. 
Following a previous report (Shinnar et al. 2001), we defined febrile convulsive status 
epileptics as febrile seizures longer than 30 min. We retrospectively reviewed the 
medical records of the patients that the attending physician diagnosed with acute 
encephalopathy at our hospital from January 2006 to December 2014. Then, we selected 
patients that met the criteria described above. The cerebrospinal fluid was examined in 
all cases, and CNS inflammation was excluded. 
There were 23 patients with acute encephalopathy with febrile convulsive status 
epilepticus as an initial neurological symptom. Among them, 11 patients (Patients 1 to 
11) had been treated with mitochondrial drug cocktails at our hospital since January 
2009 (prescription group), after informed consent was obtained from the patient’s 
family. For the mitochondrial drug cocktail, we used vitamin B1 (10 mg/kg), vitamin C 
(100 mg/kg), biotin (0.5 mg/kg), vitamin E (10 mg/kg), coenzyme Q10 (5 mg/kg), and 
L-carnitine (30 mg/kg). In all 10 patients, the 6 drugs were administered orally, except 
for 2 cases: patient 3 in which only vitamin C was administered via an intravenous drip, 
and patient 6 in which only vitamin B1 was administered through an intravenous drip. 
The cocktail administration period was defined as more than 5 days and until the 
medical condition was stable. As an additional treatment, steroid pulse therapy was 
started within 24 h of encephalopathy diagnosis in all 11 cases. A single course of 
steroid pulse therapy consisted of 30 mg/kg/day methylprednisolone for 3 days (cases 3 
and 4 received 2 courses of steroid pulse therapy). Age, trigger, clinical form, time of 
initial treatment, and sequelae were retrospectively reviewed using medical records. For 
clinical form, AESD was diagnosed by the presence of both biphasic clinical course and 
MRI findings of late reduced diffusion. 
There were 10 patients (all 6 patients with onset prior to January 2009, and 4 patients 
with the onset after January 2009, for whom we have not been involved in the initial 
treatments) with acute encephalopathy and onset of febrile convulsive status epilepticus 
at our hospital who were not treated with the mitochondrial drug cocktail (non-
prescription group; patients 12 to 21). All of the non-prescription patients also received 
steroid pulse therapy that started within 24 h of diagnosis.  
Two patients of the remaining 23 patients were excluded because only part of the six 
cocktail drugs was administered. 
Sequelae were classified as (A) no sequelae group (having no obvious functional 
decline in motor or intelligence function) or (B) sequelae group (all others). The family 
and attending physician had determined the presence or absence of sequelae at the time 
of hospital discharge. The sequelae (A vs. B) of the mitochondrial drug cocktail 
prescription and non-prescription groups were compared. In addition, the sequelae of 
the total 21 patients (A vs. B) based on the treatment initiation time, i.e., within 24 h 
and others (over 24 h and non-prescription), were analyzed.  
For statistical analysis, we employed the Fisher's exact test for comparison of case 
history between prescription group and non-prescription group, treatment initiation time 
within 24 h and others, and sequelae between the mitochondrial drug cocktail 
prescription and non-prescription groups. Student’s t-test was applied to the average age 
values in the prescription and non-prescription groups and treatment initiation time 
within 24 h and others. In all patients, blood glucose, lactate, ammonia, pH, base deficit, 
and anion gap levels were examined, and normal values were confirmed during the 
course of the study. Additionally, in the past family history of the patients, there was 
nothing relevant to congenital metabolic disorders, and patients with suspected 
congenital metabolic abnormalities were not present. There were no patients who had 
been administered valproic acid or anesthetics. This study was approved by the local 
ethics committee of Chiba Children’s Hospital. 
3. Results 
3.1 Case history 
The 21 cases are summarized in Table 1,2. For the 11 patients in the prescription group, 
patient age ranged from 7 to 171 months (mean, 44.4 months), and the trigger pathogens 
were identified as follows: human herpes virus 6 (HHV-6) (3 cases), influenza A virus 
(3 cases), rotavirus (1 case), enterovirus (1 case), and unknown (3 cases). The clinical 
form of acute encephalopathy was AESD in 7 patients and monophasic in 4 patients. 
For the 10 patients in the non-prescription group, patient age ranged from 9 to 76 
months (mean, 40.1 months), and the trigger pathogens were as follows: HHV-6 (3 
cases), influenza A virus (1 case), rotavirus (1 case), unknown (5 cases). The clinical 
form of acute encephalopathy was AESD in 4 patients and monophasic in 6 patients. 
(Table1.2) There was no significant difference in the case history both between 
prescription group and non-prescription group, and between treatment initiation time 
within 24 h and others. (Table2). In 10 cases (except for patient 8), the mitochondrial 
drug cocktail administration period was 5 to 23 days, with an average of 11.5 days. 
Patient 8 originally showed poor weight gain, and to consider the possibility of 
mitochondrial respiratory chain disorders, we continued the treatment for 10 months 
after encephalopathy until normal enzyme activity was confirmed by skin biopsy. 
3.2 Sequelae 
The distribution of the 21 patients was as follows: A, 11 cases; B, 10 cases. For the 11 
patients in the prescription group, the distribution was as follows: A, 7 cases; B, 4 cases. 
The distribution for the 10 patients in the non-prescription group was as follows: A, 4 
cases; B, 6 cases (Table 3). The patients were further divided into a biphasic group 
(AESD) and a monophasic group based on the clinical form of acute encephalopathy. 
For the 7 patients in the prescription group with AESD, the distribution was as follows: 
A, 4 cases; B, 3 cases. For the 4 patients in the non-prescription group with AEDS, the 
distribution was as follows: A, 1 case; B, 3 cases (Table 4). For the 3 patients in the 
prescription group with monophasic acute encephalopathy, the distribution was as 
follows: A, 2 cases; B, 1 case. For the 6 patients in the non-prescription group with 
monophasic acute encephalopathy, the distribution was as follows: A, 3 cases; B, 3 
cases (Table 5).  
There was no significant difference in the distribution of the severity of sequelae (A vs 
B) between the mitochondrial drug cocktail prescription and non-prescription groups in 
the total 21 patients and in both AESD and monophasic groups (Tables 3, 4, 5). 
3.3 Importance of the time of treatment initiation 
Finally, the total 21 patients’ sequelae were compared based on the mitochondrial drug 
cocktail treatment initiation time: within 24 h and others (over 24 h or non-
prescription). The sequelae of the 5 patients treated within 24 h of diagnosis were as 
follows: A, 5 cases; B, 0 cases. The sequelae of the 16 patients (treated over 24 h or 
non-prescription) were as follows: A, 10 cases; B, 11 cases. Sequelae were significantly 
better in the group administered the drug cocktail within 24 h (p = 0.035) (Table 6).  
4. Discussion 
We studied the efficacy of a mitochondrial drug cocktail in the treatment of acute 
encephalopathy with onset of febrile convulsive status epilepticus. The most important 
finding in this study was that sequelae were significantly better in the group 
administered mitochondrial drug cocktail within 24 h. 
The mechanism of acute encephalopathy with onset of febrile convulsive status 
epilepticus has not been sufficiently elucidated, and the condition is often classified into 
subtypes such as AESD, acute necrotizing encephalopathy (ANE), and other 
monophasic types in Japan (Mizuguchi et al. 2007; Yamanouchi 2011). Excitotoxic 
injury with delayed neuronal death has been hypothesized as a possible mechanism of 
AESD, based on MR spectroscopic findings (Mizuguchi et al. 2007; Takanashi 2009) 
and cytokine analysis of cerebrospinal fluid (Ichiyama et al. 2008).  
Acute encephalopathy is more common in East Asia than in Europe or North America, 
indicating that genetic factors play an important role (Chen et al. 2005; Mizuguchi et al. 
2007). Carnitine palmitoyl transferase II (CPTII) polymorphisms (Chen et al. 2005; 
Shinohara et al. 2011), SCN1A mutations (Saitoh et al. 2012), and adenosine A2A 
receptor  polymorphisms (Shinohara et al. 2013) have recently been reported as 
predisposing factors for the onset of acute encephalopathy. Among them, CPTII is the 
most likely etiological candidate for encephalopathy. A thermolabile CPTII phenotype 
and a CPTII polymorphism in Japanese patients with multiple types of acute 
encephalopathy have been reported (Chen et al. 2005; Shinohara et al. 2011). Given that 
CPTII is an enzyme localized on the mitochondrial inner membrane that removes fatty 
acids from carnitine, CPTII deficiency leads to mitochondrial dysfunction and a lack of 
energy in the wake of severe infections (Bonnefont et al. 2004; Houten and Wanders 
2010; Shinohara et al. 2011; Woeltje et al. 1990). Although further studies should target 
the relationship between CPTII polymorphism and treatment efficacy, the demonstrated 
involvement of mitochondrial dysfunction in acute encephalopathy suggests that 
mitochondrial drug cocktails should be explored for the treatment of acute 
encephalopathy (Clarke 2006). 
There are no established treatments for mitochondrial dysfunction, but various vitamins 
and coenzymes have been clinically used based on their effects on energy shortage and 
oxidative stress (Pfeffer et al. 2012), and effectiveness at high dose has already been 
reported (Panetta et al. 2004). Therefore, we employed vitamin B1 (10 mg/kg), vitamin 
C (100 mg/kg), biotin (0.5 mg/kg), vitamin E (10 mg/kg), coenzyme Q10 (5 mg/kg), 
and L-carnitine (30 mg/kg) as a mitochondrial drug cocktail based on previous reports 
(Fassone et al. 2013; Marriage et al. 2003; Panetta et al. 2004; Pfeffer et al. 2012; 
Tarnopolsky 2008). We started prescribing mitochondrial drug cocktails to patients with 
acute encephalopathy approximately 6 years ago after obtaining informed consent. 
Although the dose of the mitochondrial drug cocktail was consistent and administration 
was subject to a unified protocol, the time from diagnosis to the start of prescription 
differed among the cases because their physicians determined their applications 
independently. 
 In this study design, there was no significant difference in the average age of the 
patients in the prescription and non-prescription groups. Although no significant 
relationship has been reported between the trigger pathogen and the type of 
encephalopathy (Mizuguchi et al. 2007; Shinohara et al. 2011), we found that HHV6 
was the most common pathogen, followed by the influenza virus; this finding is in 
agreement with those of previous reports (Jones et al. 1994; Sugaya 2000).  
There was no significant difference in prognosis (A vs B) between the 
mitochondrial drug cocktail prescription and non-prescription groups among the 21 
patients and in both AESD and monophasic groups, probably because of the small 
number of patients and the delay in starting the mitochondrial drug cocktail after the 
diagnosis of encephalopathy. However, no sequelae were observed in the 5 cases in 
which mitochondrial drug cocktail administration was initiated within 24 h of 
encephalopathy diagnosis. Given that the outcome was significantly better in the group 
administered the mitochondrial drug cocktails within 24 h, we consider that early 
administration within 24 h of diagnosis may provide a prophylactic effect. 
Although there are reports of various vitamins and coenzymes as treatments for 
mitochondrial diseases (Fassone et al. 2013; Marriage et al. 2003; Panetta et al. 2004; 
Pfeffer et al. 2012; Tarnopolsky 2008) and a report of the combination of creatine 
monohydrate, coenzyme Q10, and alpha-lipoic acid as a “mitochondrial cocktail” for 
mitochondrial cytopathies (Fassone et al. 2013), there are no reports in which a 
combination of various vitamins and coenzymes was administered for acute 
encephalopathy. Considering the mechanisms of these constituents, it is likely that the 
mitochondrial drug cocktail used in this study provides an effective treatment for acute 
encephalopathy. Moreover, there have been no obvious side effects in our patients, and 
administration of the drug cocktail was relatively easy.  
The limitations of our study stem from retrospective analysis and the small number 
of patient, further prospective study in larger cohorts is necessary to conclude the 
observations; however, we consider that speedy administration of mitochondrial drug 
cocktails is worthwhile in cases of acute encephalopathy and in individuals with a high 
risk of encephalopathy (such as those with status epilepticus or spasm of the cluster 
associated with fever) because of the potential to prevent the development of sequelae 
or the onset of acute encephalopathy.  
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Table 1.  Summary of the 21 patients 
Patient 
 
Gender Age 
(months) 
Triggers Clinical 
form 
Sequelae 
1 M 62 Influenza A virus monophasic A 
2 F 13 HHV-6 monophasic A 
3 M 13 HHV-6 AESD A 
4 F 7 HHV-6 AESD A 
5 M 171 Influenza A virus monophasic A 
6 F 63 Enterovirus AESD B 
7 F 64 unknown monophasic B 
8 F 36 Rotavirus AESD A 
9 M 21 unknown AESD B 
10 F 28 Influenza A virus AESD A  
11 F 11 unknown AESD B 
12 F 19 Influenza A virus monophasic B 
13 M 14 unknown monophasic A 
14 M 9 HHV-6 AESD A 
15 F 76 unknown monophasic B 
16 F 17 HHV-6 AESD B 
17 F 58 unknown monophasic B 
18 M 72 unknown AESD B 
19 F 35 unknown monophasic A 
20 F 47 Rota virus monophasic A 
21 F 54 HHV-6 AESD B 
Sequelae were classified as A; no, B; mild-moderate, or C; severe.  
Patients administered the mitochondrial drug cocktail are colored gray (within 24 h 
are colored dark gray). 
  
 
Table2.  Comparison of patients case history  
 Prescription and non-prescription 
n=21 
Treatment initiation time 
n=21 
Prescription 
 
n=11 
Non- 
prescription 
n=10 
p 
Value 
Within 24 h 
 
n=5 
Others 
 
n=16 
p 
Value 
Median Age 
(months) 
44.4 40.1 0.798 53.2 39.0 0.474 
Gender 
(male) 
4 3 1.000 3 4 0.182 
Trigger       
 HHV-6 3 3 1.000 3 3 0.115 
Influenza A  3 1 0.587 2 2 0.228 
Rota 1 1 1.000 0 2 1.000 
Entero 1 0 1.000 0 1 1.000 
unkown 3 5 0.268 0 8 0.111 
Clinical form 
(AESD) 
7 4 0.395 2 9 0.635 
 
 
 Table 3.  The effect of the mitochondrial drug cocktail (total 21 patients). 
Group A: None B: Sequelae 
 
Total p Value 
Prescription 7 (33%) 4 (19%) 
 
11 (48%) 0.395 
Non-prescription 4 (19%) 6 (29%) 
 
10 (48%) 
Total 11 (52%) 10 (52%) 
 
21 (100%)   
 
 
Table 4.  Effect of the mitochondrial drug cocktail (11 AESD patients).  
Group A: None B: Sequelae 
 
Total p Value 
Prescription 4 (36%) 3 (27%) 
 
7 (64%) 0.303 
Non-prescription 1 (9%) 3 (27%) 
 
4 (36%) 
Total 5 (45%) 6 (55%) 
 
11 (100%)  
 
 
Table 5.  Effect of the mitochondrial drug cocktail (10 monophasic patients). 
Group A: None B: Sequelae Total p Value 
Prescription 3 (30%) 1 (10%) 
 
3 (30%) 0.571 
Non-prescription 3 (30%) 3 (30%) 
 
6 (60%) 
Total 6 (60%) 4 (40%) 
 
10 (100%)  
 
 
Table 6.  Effect of the mitochondrial drug cocktail (total 21 patients based on 
the treatment initiation time: within 24 hours vs. others).  
Treatment initiation 
time 
A: None B: Sequelae Total p Value 
Within 24 h 5 (24%) 0 (0%) 
 
5 (24%) 0.035 
Others (over 24 h or 
non-prescription) 
6 (28%) 10 (48%) 
 
16 (76%) 
Total 11 (52%) 10 (48%) 
 
21 (100%)  
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